文献速递类风湿关节炎

微型迷走神经刺激装置治疗多重耐药类风湿关节炎的安全性与疗效:两阶段多中心随机先导研究

Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study.
PubMed 文献 · Lancet Rheumatol · 2020-07-28

该研究为首次人体两阶段多中心随机先导试验,纳入14例对至少两种不同作用机制的生物制剂或JAK抑制剂应答不足的中重度活动性类风湿关节炎患者,评估微型迷走神经刺激装置的安全性。第一阶段开放标签植入并每日刺激1分钟,第二阶段随机分配至每日1次、每日4次主动刺激或不激活假刺激12周。未发生装置相关或治疗相关严重不良事件,手术相关不良事件为Horner综合征和声带麻痹各1例且均无临床显著后遗症,临床疗效作为关键次要结局显示可减轻疾病症状。

要点

  • 微型VNS装置在多重耐药RA患者中未出现装置或治疗相关严重不良事件。
  • 手术相关不良事件为Horner综合征和声带麻痹各1例,均自行缓解无后遗症。
  • VNS可减轻多重耐药RA患者的疾病症状,支持开展更大规模随机假对照研究。

核心结论

  • 微型迷走神经刺激装置治疗多重耐药类风湿关节炎安全且耐受良好,并减轻疾病症状。

研究设计与样本

  • 两阶段多中心随机先导研究,在美国5个临床研究中心开展,共纳入14例对至少两种不同作用机制的生物制剂或JAK抑制剂应答不足的中重度活动性RA患者。
  • 第一阶段为开放标签,3例患者植入微型VNS装置并每日激活1分钟;第二阶段11例患者按1:1:1随机分配至每日1次刺激(n=3)、每日4次刺激(n=4)或不激活假刺激(n=4),为期12周,研究者和患者对分组设盲。

主要发现

  • 未发生装置相关或治疗相关严重不良事件,未记录死亡。
  • 手术相关不良事件为Horner综合征和声带麻痹各1例,均无临床显著后遗症自行缓解。
  • 临床疗效作为关键次要结局,VNS减轻了多重耐药RA患者的疾病症状。

关键数值与推荐

  • 主要结局为治疗中出现的不良事件发生率;临床疗效作为关键次要结局评估。
  • 14例患者于2018年3月13日至8月8日入组。

临床怎么用

  • 对于对多种生物制剂或JAK抑制剂应答不足的中重度活动性RA患者,微型VNS装置可能作为潜在治疗选择,但需更大规模随机假对照研究进一步验证。

局限性

  • 样本量小(共14例),为先导性研究,疗效证据有限。
  • 第一阶段为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Background The inflammatory reflex plays a role in regulating innate and adaptive immunity by modulating cellular and molecular inflammatory pathways. The vagus nerve is a major constituent of the inflammatory reflex and studies have shown that the reflex can be activated by electrical stimulation of the vagus nerve. In this first in-human pilot study, we assessed the safety and efficacy of a novel miniaturised vagus nerve stimulation (VNS) device for the treatment of multidrug-refractory rheumatoid arthritis. METHODS: Participants with moderately to severely active rheumatoid arthritis and prior insufficient response to two or more biological disease-modifying anti-rheumatic drugs or Janus kinase inhibitors with at least two different modes of action were enrolled in a two-stage study done at five clinical research sites in the USA. Stage 1 was open label; participants were implanted with a miniaturised VNS device, which was activated for 1 min once a day. In stage 2, participants were randomly assigned (1:1:1) to receive active stimulation (1 min once a day or 1 min four times a day) or sham stimulation (device implanted but not activated), with the sites and participants masked to treatment assignment. The primary outcome was incidence of treatment-emergent adverse events. Clinical efficacy was assessed as a key secondary outcome. The study was registered with ClinicalTrials.gov, NCT03437473. FINDINGS: 14 patients were enrolled between March 13 and Aug 8, 2018. Three patients received stimulation in stage 1 and, following safety review board approval, the remaining 11 patients were implanted during stage 2 and randomly assigned to receive 1 min of stimulation once daily (n=3), 1 min of stimulation four times daily (n=4), or no stimulation (n=4) for 12 weeks. There were no device-related or treatment-related serious adverse events. Surgery-related adverse events were Horner's syndrome and vocal cord paralysis (in one patient each), which resolved without clinically significant sequelae. No deaths were recorded. INTERPRETATION: VNS with a miniaturised neurostimulator was safe and well tolerated and reduced signs and symptoms of rheumatoid arthritis in patients with multidrug-refractory disease. These results support further evaluation in a larger randomised sham-controlled study. FUNDING: SetPoint Medical.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatol. 2020. PMID: 38273617. doi:10.1016/S2665-9913(20)30172-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。